Skip to main content
Equibles
KROS logo

KROS · Keros Therapeutics, Inc. · Metrics

Track KROS — free

Use KROS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KROS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.08 +0.54 (+5.66%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$197.81M
Shares
19.62M
Volume · Nov 12 630.16K Avg daily vol (3M) 187.94K

KROS metrics

77 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.08
Market cap
$197.81M

Price action

23 metrics
Price change (1W)
-11.9%
Price change (30D)
-15.0%
Price change (3M)
-14.8%
Price change (6M)
-20.4%
Price change (YTD)
-53.1%
Price change (1Y)
-43.6%
Trailing year
Price change (5Y)
-83.9%
52-week high
$21.84
52-week low
$9.17
Change from 52-week high
-56.3%
Change from 52-week low
+4.0%
Annualized volatility
51.0%
Annualized volatility (3M)
49.6%
Implied volatility (30D)
100.9%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.3
RSI (14D)
33.7
Price vs SMA 50
-13.9%
Price vs SMA 200
-18.5%
Avg volume (3M)
180,701
Relative volume
1.2
Average dollar volume
$1.99M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
19.62M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-1.8×
EV / EBITDA
—
EV / EBIT
—
P / sales
4.6×
reciprocal yield 21.6%
P / book
0.7
reciprocal yield 149.1%
FCF yield
-25.8%
TTM · current market cap
Buyback yield
201.1%
P / FCF
—
P / operating cash flow
—
Earnings yield
-33.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
8,895.0×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
7,533.4×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
201.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-08-07

Profitability

9 metrics
Gross margin
—
Operating margin
-181.3%
Trailing 12 months
Net margin
-152.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$73.27M
Net income (TTM)
−$61.73M
Trailing 12 months
Diluted EPS (TTM)
$-2.34
FCF margin
-119.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$15.51

Growth

11 metrics
Revenue growth YoY
+183.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$40.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-49.9%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-22.1%
Return on assets
-20.1%
Debt / equity
0.0
Current ratio
18.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$48.27M
Quick ratio
18.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$259.46M
Latest balance sheet
Cash & equivalents
$259.46M
Total assets
$307.37M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$47.85M
Capital expenditures (TTM)
$421,000
R&D (TTM)
$76.83M
SG&A (TTM)
—
Stock compensation (TTM)
$23.08M
R&D / revenue
190.1%
Stock compensation / revenue
57.1%

Ownership (13F)

9 metrics
13F filers
132
13F filer change QoQ
-19
Institutional ownership
94.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
47.6%
Private-fund adviser ownership
45.2%
Active holders' share change QoQ
+0.1%
Holder tenure
11.1
Price vs estimated holder cost
-54.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.5%

Short interest

3 metrics
Short interest
5.5%
Latest settlement · 7.1 days to cover
Days to cover
7.1d
Short-squeeze score
52 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$90,866
Insider-sentiment score
30 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1664710 CUSIP 492327101 13F (30d) 85 filings 70 filers Visit website Investor relations